Introduction
The theme of this meeting is peculiarly apt to the policy of our new Section, namely, to concentrate upon questions of clinical oncology and to stimulate interchange between the clinical contribution and experimental cancer research. Tumour immunology and the prospects of an immunotherapy have a long and varied history. A central topic of the German literature of pathology in the last century was the extent to which, if indeed at all, signs might be detected, by histological or other methods, of a cellular somatic reaction against the growth of autochthonous tumours. Such endeavours were largely inconclusive or negative, although much later (in the 1920s) came the pioneering observations of J B Murphy, at the Rockefeller Institute, of a possibly defensive lymphocyte infiltration in many tumours of animals. Tumour immunology was my first love when I entered the cancer field in 1929. At that time, much work was ill-conceived or ephemeral, and the same year saw Woglom's (1929) classic review in which the celebrated American oncologist surveyed some hundreds of papers, only to find a mere handful likely to hold any lasting or permanent interest. From that day to this, tumour immunology has waxed and waned. The present intense revival is partly due to the modem development of immunological techniques of great sophistication and delicacy, and partly to the concurrent emergence of new ideasoften of the utmost brilliance; but it also reflects the continuing and fascinating logic of the immune approach. It is natural that these developments should hold out fresh prospects, at long last, of a useful immunotherapy, and it is vital that these developments be pursued with the utmost vigour, both clinically and experimentally, always provided that such work is without prejudice to the investigation of other forms of attack. In spite of a momentary over-optimism in certain quarters, it is probable that those who have made the greatest contributions to recent tumour immunology, and who possess the deepest knowledge of it, are perhaps the most cautious and least sanguine. Hence the prospects of immunotherapy must be assayed with utmost balance, and our purpose must be, as in every other department of cancer research, to stimulate both clinical interest and new experiments, while simultaneously repressing unjustified enthusiasm and prejudgment. Tumour-associated antigens which elicit immune responses in the host have been conclusively demonstrated in experimental tumours of many types including those induced by chemical carcinogens and viruses as well as spontaneously arising tumours where the etiology is unknown. These antigens in experimental tumours have frequently been described as tumour-specific transplantation antigens because of their capacity to elicit immunity against tumour cells transplanted into syngeneic recipients, but since they are also recognized by the autochthonous host, a more apt description is tumour rejection antigen. Tumours induced by chemical or physical agents express individually distinct tumour antigens so that immunization against one tumour does not confer on the host resistance to other tumours even when they are induced by the same carcinogen (Baldwin 1970) . Virus-induced tumours, however, contain cross-reacting antigens showing virus-related specificities and immunization against one tumour affords protection against other tumours induced by the same virus, but not those induced by other viruses (Habel 1969 , Pasternak 1969 . For some considerable time, this difference in the specificities of antigens associated with tumours induced by chemical carcinogens and oncogenic viruses was held to be important in that it provided a method for determining the etiology of spontaneous tumours and possibly, also, human tumours. Since, however, mammary tumours induced by the mammary tumour virus have individually specific antigens (Morton et al. 1969 , Vaage et al. 1969 ) as well as common antigens coded for by the virus, this distinction is less clear and definition of the antigenic specificities of a tumour does not provide conclusive evidence of its etiology.
REFERENCE
The definition of tumour antigens as specific tumour products is in some cases now questionable. Cell surface antigens on certain virusinduced tumours and leukemias are viruscontrolled products (Pasternak 1969) . Also some tumour antigens are detectable in embryonic tissue although not adult host tissues. Included in this category is the so-called carcinoembryonic antigen of colon carcinoma (Gold & Freedman 1965 , von Kleist & Burtin 1969 and the afcetoprotein associated with hepatocellular carcinoma (Abelev 1968 ). Several experimental tumours including SV-40 virus-induced hamster and guinea-pig tumours (Duff & Rapp 1970 ) and chemically-induced rat hepatomas and sarcomas (Baldwin, Glaves, Harris & Price 1971) also express cell surface antigens which are present in embryonic tissues. As far as the chemicallyinduced tumours are concerned, the embryonic antigens differ from the individually distinct tumour-associated antigens in that they are common to several tumour types (Baldwin, Glaves, Harris & Price 1971) . Moreover, the individual tumour antigens are primarily responsible for the immune response elicited against these tumours, since cross-resistance cannot be demonstrated (Baldwin & Barker 1967a) .
MEDIATION OF TUMOUR-IMMUNE RESPONSES
Cell-mediated Reactions Tumour-associated rejection antigens are generally localized at the cell surface either in, or close to, the plasma membrane and the immune response they elicit resembles a weak allograft reaction. Consequently, it is generally accepted that cell-mediated immune responses play a major role in tumour rejection. This has been experimentally demonstrated in numerous studies by the adoptive transfer of tumour immunity with lymphoid cells from immunized donors (Baldwin & Barker 1967a , Alexander & Hall 1970 . Sensitized lymphoid cells have been used also to suppress growth of primary and transplanted tumours (Alexander & Hall 1970) , indicating their potential for immunotherapy. Cell-mediated tumourimmune reactions can also be demonstrated in vitro and a notable advance, making possible studies of human tumours, was the development of the colony inhibition technique (Hellstrom & Hellstr6m 1969) . In this test, tumour cells plated in tissue culture are exposed to lymphocytes and the inhibitory effect assessed from the number of tumour colonies formed, compared with the effect of lymphocytes from normal donors. Cellmediated immune suppression of colony formation cells of both virus and chemically-induced animal tumours has been detected by this method , 1970 , Baldwin & Embleton 1971 . Analysis of the reactions to chemically-induced rat hepatomas (Baldwin & Embleton 1971) , where each tumour carries an individually distinct tumour rejection antigen, has been especially valuable in providing a critical appraisal of the validity of colony-inhibition methods for detecting tumour-specific immune reactions. Cytotoxic reactions of blood lymphocytes from patients with various types of tumour against their own malignant cells have now been observed (Hellstr6m & Hellstrom 1969, Hell-str6m, Hellstr6m, Sj6gren & Warner 1971), although the most conclusive evidence so far has been obtained in studies of patients with neuroblastoma (Hellstrom, Hellstrom, Bill, Pierce & Yang 1970 ) and carcinomas of the colon (Hell-str6m, Hellstrom & Shepard 1970) and bladder (Bubenik et al. 1970) . Although more extensive investigations are necessary, two points emerge from the evidence so far available. First, blood lymphocytes from a patient with one type of malignancy are cytotoxic for morphologically similar tumours from other patients but not for unrelated types of tumours. This implies that human tumours express tumour-type specific antigens. Secondly, peripheral lymphocytes from tumour-bearing patients, in a high proportion of cases, were no less cytotoxic than those from clinically symptom-free patients. This latter finding, substantiated in experimental animal studies (Hellstrom & Hellstr6m 1970) , of circulating sensitized lymphocytes in the presence of tumour, implies that other factors may be operating antagonistically in the overall immune response to tumour-associated antigens.
Humoral Antibody Reactions Serum antibody directed against tumour-associated antigens on experimental animal tumours can be demonstrated in several ways. Leukemic Section of Oncology with Section ofClinical Immunology & Allergy 1041 cells are sensitive to tumour-specific antibody in the presence of complement and cytotoxic tests have been used to characterize antigen systems associated with virus-induced murine leukwmias (Old & Boyse 1965 , Pasternak 1969 . For reasons not yet clear, cells of solid tumours are insensitive in vitro to cytotoxic antibody but tumourassociated antigens can be detected in some tumours by membrane immunofluorescence methods. For example, individually distinct tumour antigens on the surface of chemicallyinduced rat hepatomas (Baldwin & Barker 1967b ) and sarcomas (Baldwin, Barker, Embleton, Glaves, Moore & Pimm 1971) have been identified by membrane immunofluorescence tests with viable tumour cells in suspension. Cell surface antigens on several types of human tumours are also demonstrable by membrane inumunofluorescence methods. These include Burkitt's lymphoma and nasopharyngeal carcinoma where cross-reacting tumour antigens are detected and undoubtedly these are EB-virus-associated antigens. On the other hand, melanoma cells express individually distinct antigens (Lewis et al. 1969) which are comparable in specificity to those observed on chemically-induced animal tumours. The situation, here, is complicated by the observation of common antigenicities (Morton et al. 1968 , Hellstrom, Hellstr6m, Sjogren & Warner 1971 ) and further characterization of these antigens is needed.
Although antibody directed against tumourassociated antigens can be demonstrated in several animal systems, its role in tumour rejection reactions is not clear. Passive transfer of serum from tumour-immune donors, except in the case of the leuklcmias, does not inhibit tumour growth and may even lead to enhancement. It is now clear, however, that tests on the passive transfer of tumour resistance with serum provide an inadequate appraisal of the role of serum factors. For instance, serum from rats immediately following excision of subcutaneous grafts of transplanted rat sarcomas effectively suppressed growth of tumour cells although antibody was not detectable in the serum by membrane immunofluorescence tests. Following subsequent repeated immunization with subthreshold doses of tumour cells to a point where circulating antibody was detectable by immunofluorescence assay, the serum was no longer cytotoxic as measured by inhibition of tumour growth.
The observations by the Hellstr6ms, in studies with both experimental animal and human tumours, of cytotoxic lymphocytes from both tumour-bearing and tumour-free donors (Hell-str6m & Hellstrom 1969 , 1970 prompted them to examine whether serum factors may be acting antagonistically in tumour-bearing hosts. This led to the finding that serum from tumour-bearing indi-viduals contains circulating blocking substances (antibody) so that pre-treatment of tumour cells in vitro with serum abrogates the cytotoxic effect of sensitized lymphocytes as measured by inhibition of colony formation by tumour cells , Hellstrom, Sjogren, Warner & Hellstrom 1971 . A further important observation was that serum-blocking factors were rapidly lost from both experimental animal and human cases following tumour removal and present evidence suggests that the blocking activity is associated with either antibody, possibly of the 7S-immunoglobulin class, or circulating antigen-antibody complexes. Comparable studies have provided an explanation for the variable effects of serum from rats immunized against rat sarcomas to transfer tumour resistance passively. Thus serum taken following surgical excision of developing tumours was shown, by colony inhibition methods, to contain cytotoxic antibody, but no blocking antibody which interfered with sensitized lymphocytes. Serum from repeatedly immunized rats, on the other hand, contained both cytotoxic and blocking antibody. In this case, the appearance of blocking activity in serum correlated with the presence of antibody detected by membrane immunofluorescence methods which is almost certainly 7S-immunoglobulin. In other studies, immunization with isolated plasma membrane fractions from rat hepatomas, which are known to retain tumour-specific antigen (Baldwin & Moore 1969) , did not result in the development of tumour immunity. Analysis of this form of immunization indicated that the most consistent response was the production of serum antibody, at least part of which showed blocking activity against sensitized lymphocytes. Under these conditions of immunization, therefore, a 'nonprotective' type of response, predominantly of a humoral antibody type, was elicited and it was further shown that this rendered the animals unresponsive to other forms of immunotherapy which normally produce tumour immunity.
Studies on the immune response to antigens associated with experimental animal tumours thus provide important guide lines for evaluating the usefulness of immunotherapy of human tumours. To begin with, in selecting human tumours for immunotherapy, they should be shown to express tumour-specific antigens which evoke immune responses in the patient. Secondly, the methods used for immunotherapy should predominantly influence the cell-mediated response and if possible there should be no concomitant increase in circulating antibody. There is some evidence, although not yet sufficient, that a developing tumour may itself produce a significant lymphocyte-mediated immune response, in which case more pronounced antigenic stimulation may not always result in a heightened im-mune reaction. In this case, procedures designed to increase lymphocyte reactivity nonspecifically or to produce localized responses at the tumour sites are more clearly indicated. Finally, administration of tumour antigen preparations such as isolated membrane fractions should be viewed with caution since the experience from experimental studies is that this may produce an enhancing response.
Immunotherapy of Experimental Tumours 'Escape' ofautologous tumours: The possible ways by which some immunological procedures may be of therapeutic benefit must be discussed in relation to the basic problem of 'escape', i.e. why malignant cells with tumour-specific antigens in their membranes are successful and not rejected like allografts of normal tissues. A number of different escape mechanisms have been postulated: (1) That the tumour-bearing host has an impaired immune system. It is now abundantly clear that any immune defect in cancer patients is a consequence of advanced disease and not its cause. While immunosuppression may in some instances facilitate the induction of tumours, immunosuppression is not an essential component of successful tumour growth. (2) That tumour-bearing animals are specifically tolerant to the tumour-specific antigens. Recent work has shown that in most animal tumours the host is capable of recognizing the tumour-specific antigens of its own autologous tumour even though the immune reaction which results from this recognition is obviously inadequate. (3) That tumours are protected from destruction by cytotoxic lymphocytes, as a result of being coated with a non-complement-binding antibody which masks the tumour-specific antigens without affecting the growth rate of the cells so coated. We have been quite unable, in human and in animal tumours, to find evidence that the cells of autologous tumours are blocked in this way by antibody. To question the existence of protection by antibody is not in conflict with the well-established phenomenon of immunological enhancement because the mechanisms are quite different.
Consideration of infectious diseases provides abundant evidence for the view that escape from immune defences of the host can occur without the intervention of specific mechanisms such as those listed above. Infectious agents persist because the immune responses of the body are not expressed equally at all sites and the effectiveness of the different effector mechanisms is limited by physiological and immunological factors. In the destruction of antigenic cells in vivo three mechanisms have to be considered: antibody acting in conjunction with complement; macrophages which have become specifically sensitized; and cytotoxic lymphoid cells. Cytotoxic antibodies: Circulating antibody, and particularly the very cytotoxic macroglobulins, are, because of their size, confined largely to the vascular compartments. Their concentration at extravascular sites is much lower than in the blood. This explains why antibodies directed against tumour-specific antigens are of relatively little value for immunotherapy. Such antisera are only able to destroy cells which are readily accessible. Specifically immune macrophages: Specifically cytotoxic macrophages are produced as the result of interaction with immune lymphoid cells; possibly the latter produce an antigenically specific cytophilic factor which coats the macrophages. These immune macrophages are capable of protecting the peritoneal cavity and possibly the lung. They are not, however, very effective in attacking subcutaneous tumours unless ancillary inflammatory reactions are induced which promote the entrance of macrophages. It is possible that the retardation of tumour growth which has been achieved in some systems by treating animals bearing tumours with nonspecific
